Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of Rivaroxaban 20 mg film-coated tablets under fed conditions in healthy Thai volunteers
TCTR20170614003Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in venous thromboembolism (VTE), Atrial fibrillation (AFib) and pulmonary embolism (PE) (2 arms), sponsored by Bio-innova. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)pulmonary embolism (PE)
Beyond the preview
Go deeper on TCTR20170614003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20170614003.